- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Venetoclax, Zanubrutinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 4
- States / cities
- Scarborough, Maine • Boston, Massachusetts • South Weymouth, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 909
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma
- Interventions
- fludarabine phosphate, octreotide acetate
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2015
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, epirubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, B-Cell Diffuse Lymphoma
- Interventions
- PCI-32765
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 16
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts + 11 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Pirtobrutinib, Venetoclax
- Procedure · Drug
- Lead sponsor
- Kerry Rogers
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- dasatinib, Rituximab, fludarabine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Rituximab, Fludarabine phosphate, Leukemic or stroma cells
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Lisocabtagene maraleucel
- Biological
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2044
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Esophageal Cancer, Lung Cancer, Lymphoma
- Interventions
- topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2000
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- psychosocial assessment and care
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
- Interventions
- biologic sample preservation procedure, cytology specimen collection procedure
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2040
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
- Interventions
- rituximab, bendamustine, lenalidomide
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 17
- States / cities
- Clive, Iowa • Des Moines, Iowa • Sioux City, Iowa + 3 more
- Conditions
- Lymphoid Leukemia in Remission, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
- Interventions
- Tositumomab and Iodine I 131 Tositumomab
- Combination Product
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- everolimus, lapatinib ditosylate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Venetoclax, Zanubrutinib
- Procedure · Drug
- Lead sponsor
- Kerry Rogers
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- ABT-199, Rituximab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 4
- States / cities
- La Jolla, California • Chicago, Illinois • New Hyde Park, New York + 1 more
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- CC-122, Ibrutinib, Obinutuzumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 8
- States / cities
- La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, sargramostim, carmustine, cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1988 – 1991
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Small Lymphocytic Lymphoma
- Interventions
- apolizumab, laboratory biomarker analysis, pharmacological study
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 2
- States / cities
- La Jolla, California • Columbus, Ohio
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- B-cell Small Lymphocytic Lymphoma Recurrent
- Interventions
- TRU-016, Bendamustine, Rituximab
- Drug
- Lead sponsor
- Aptevo Therapeutics
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Augusta, Georgia • Omaha, Nebraska + 3 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Worcester, Massachusetts • Columbia, South Carolina + 1 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration, Venetoclax
- Procedure · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 624
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 443 more